Literature DB >> 21969294

Effect of glaucoma on the quality of life of young patients.

Viney Gupta1, Paromita Dutta, Mary OV, Kulwant Singh Kapoor, Ramanjit Sihota, Guresh Kumar.   

Abstract

PURPOSE: To evaluate the quality of life (QOL) of juvenile-onset primary open-angle glaucoma (JOAG) patients by using a utility-based assessment.
METHODS: QOL using time-tradeoff utility values was analyzed in 70 JOAG patients and compared with 108 adult-onset POAG patients. The relationships of utility values to parameters like age at diagnosis, visual acuity, mean deviation, number of medications and surgery, duration of the disease, level of education, and socioeconomic status were assessed.
RESULTS: The mean age at diagnosis of JOAG patients was 26 ± 9.8 years, whereas that of the adult onset POAG patients was 62 ± 11.2 years. Overall, there was a decrease in utility values with increasing age (r = -0.3; P < 0.001). The mean utility score among JOAG patients was (0.80 ± 0.18) significantly greater than among adult POAG patients (0.64 ± 0.28; P < 0.001). The differences in utility scores between JOAG and adult POAG patients were significant when adjusted for differences in better eye visual acuity, mean deviation, and the presence of systemic comorbidity among adults (P = 0.02). Among JOAG patients, those needing topical antiglaucoma medications and those with visual acuity worse than 6/12 in the better eye had lower utility values (P = 0.008 and P = 0.002, respectively).
CONCLUSIONS: Utility values among glaucoma patients in the juvenile age group are better than those of adult POAG patients. Decreasing vision in the better eye and having to use medication decrease the utility scores among young patients with glaucoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21969294     DOI: 10.1167/iovs.11-7551

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  8 in total

Review 1.  Juvenile-onset open-angle glaucoma - A clinical and genetic update.

Authors:  Harathy Selvan; Shikha Gupta; Janey L Wiggs; Viney Gupta
Journal:  Surv Ophthalmol       Date:  2021-09-16       Impact factor: 6.197

2.  Cost Analysis of Commonly used Combination of Drugs in Primary Open Angle Glaucoma.

Authors:  Shivaprasad Kalakappa Kumbar; Mrutyunjay Mirje; Gurudatta Moharir; Ambadasu Bharatha
Journal:  J Clin Diagn Res       Date:  2015-05-01

Review 3.  Mental stress as consequence and cause of vision loss: the dawn of psychosomatic ophthalmology for preventive and personalized medicine.

Authors:  Bernhard A Sabel; Jiaqi Wang; Lizbeth Cárdenas-Morales; Muneeb Faiq; Christine Heim
Journal:  EPMA J       Date:  2018-05-09       Impact factor: 6.543

4.  Cross-Sectional Study on the Coping Strategies Among Glaucoma Patients Attending a Secondary Eye Clinic in Calabar, Nigeria.

Authors:  Egbula Nkanu Eni; Bassey Eyo Edet; Affiong Andem Ibanga; Roseline Ekanem Duke
Journal:  Clin Ophthalmol       Date:  2020-05-13

5.  Low-energy Selective Laser Trabeculoplasty Repeated Annually: Rationale for the COAST Trial.

Authors:  Tony Realini; Gus Gazzard; Mark Latina; Michael Kass
Journal:  J Glaucoma       Date:  2021-07-01       Impact factor: 2.290

6.  Medication Adherence and Persistence of Open-Angle Glaucoma Patients in Korea: A Retrospective Study Using National Health Insurance Claims Data.

Authors:  Yunjeong Jang; Donghyun Jee; Donghwan Lee; Nam-Kyong Choi; SeungJin Bae
Journal:  Int J Environ Res Public Health       Date:  2021-04-13       Impact factor: 3.390

7.  Vision Health-Related Quality of Life in Chinese Glaucoma Patients.

Authors:  Lei Zuo; Haidong Zou; Jianhong Zhang; Xinfeng Fei; Xun Xu
Journal:  J Ophthalmol       Date:  2015-10-07       Impact factor: 1.909

8.  Impact of Visual Impairment on the Wellbeing and Functional Disability of Patients with Glaucoma in India.

Authors:  Suneeta Dubey; Harleen Bedi; Manveen Bedi; Preeti Matah; Jigyasa Sahu; Saptarshi Mukherjee; Lokesh Chauhan
Journal:  J Curr Ophthalmol       Date:  2020-03-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.